TG Therapeutics (NASDAQ:TGTX) Stock Rating Reaffirmed by LADENBURG THALM/SH SH

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reissued by LADENBURG THALM/SH SH in a research note issued to investors on Thursday, Benzinga reports. They presently have a $39.00 price objective on the biopharmaceutical company’s stock. LADENBURG THALM/SH SH’s price target would indicate a potential upside of 183.02% from the stock’s current price.

TGTX has been the subject of several other research reports. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 price target on shares of TG Therapeutics in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of TG Therapeutics in a report on Thursday. B. Riley increased their target price on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. Finally, StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

TG Therapeutics Stock Down 1.5 %

Shares of TGTX stock opened at $13.78 on Thursday. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $35.67. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The firm has a market cap of $2.13 billion, a PE ratio of 689.34 and a beta of 2.30. The stock has a 50 day moving average of $15.11 and a 200-day moving average of $13.91.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The firm had revenue of $43.97 million during the quarter, compared to analysts’ expectations of $40.06 million. During the same period in the prior year, the company earned ($0.39) EPS. On average, equities analysts predict that TG Therapeutics will post -0.12 EPS for the current year.

Insider Activity

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TGTX. Advisor Group Holdings Inc. raised its stake in shares of TG Therapeutics by 49.5% during the first quarter. Advisor Group Holdings Inc. now owns 34,433 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 11,406 shares during the last quarter. Raymond James & Associates raised its position in shares of TG Therapeutics by 4.3% during the 1st quarter. Raymond James & Associates now owns 165,994 shares of the biopharmaceutical company’s stock valued at $1,579,000 after acquiring an additional 6,860 shares during the last quarter. HighTower Advisors LLC raised its position in shares of TG Therapeutics by 28.3% during the 1st quarter. HighTower Advisors LLC now owns 13,603 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 2,998 shares during the last quarter. MetLife Investment Management LLC lifted its stake in TG Therapeutics by 59.0% in the first quarter. MetLife Investment Management LLC now owns 71,269 shares of the biopharmaceutical company’s stock valued at $678,000 after buying an additional 26,443 shares during the period. Finally, BlackRock Inc. boosted its stake in TG Therapeutics by 0.4% during the 1st quarter. BlackRock Inc. now owns 8,935,578 shares of the biopharmaceutical company’s stock worth $84,978,000 after acquiring an additional 33,413 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.